Tech Company Financing Transactions
Slate Pharmaceuticals Funding Round
T+T Holdings and private investors invested in a $5 million Series A funding round for Slate Pharmaceuticals. The round was announced by the company on 7/25/2008.
Transaction Overview
Company Name
Announced On
7/25/2008
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Series A
Investors
T+T Holdings (Lead Investor) (Trygve Mikkelsen)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
318 Blackwell Street 240
Durham, NC 27701
USA
Durham, NC 27701
USA
Phone
Website
Email Address
Overview
Slate Pharmaceuticals, Inc. was founded in 2007 and The company markets an FDA approved subcutaneous implantable testosterone pellet used for the treatment of testosterone deficiency in aging men as well as androgen deficiency caused by other conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bob Whitehead
Browse more venture capital transactions:
Prev: 7/25/2008: Cara Therapeutics venture capital transaction
Next: 7/25/2008: Sensys Networks venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs